Aptose Biosciences Stock Alpha and Beta Analysis
| APTO Stock | USD 0.18 0.01 5.26% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Aptose Biosciences. It also helps investors analyze the systematic and unsystematic risks associated with investing in Aptose Biosciences over a specified time horizon. Remember, high Aptose Biosciences' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Aptose Biosciences' market risk premium analysis include:
Beta (0.75) | Alpha (0.88) | Risk 5.47 | Sharpe Ratio (0.21) | Expected Return (1.14) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Aptose |
Aptose Biosciences Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Aptose Biosciences market risk premium is the additional return an investor will receive from holding Aptose Biosciences long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Aptose Biosciences. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Aptose Biosciences' performance over market.| α | -0.88 | β | -0.75 |
Aptose Biosciences expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Aptose Biosciences' Buy-and-hold return. Our buy-and-hold chart shows how Aptose Biosciences performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Aptose Biosciences Market Price Analysis
Market price analysis indicators help investors to evaluate how Aptose Biosciences stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Aptose Biosciences shares will generate the highest return on investment. By understating and applying Aptose Biosciences stock market price indicators, traders can identify Aptose Biosciences position entry and exit signals to maximize returns.
Aptose Biosciences Return and Market Media
The median price of Aptose Biosciences for the period between Wed, Aug 28, 2024 and Tue, Nov 26, 2024 is 0.39 with a coefficient of variation of 9.79. The daily time series for the period is distributed with a sample standard deviation of 0.04, arithmetic mean of 0.38, and mean deviation of 0.02. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Acquisition by Whitehead Warren of 7000 shares of Aptose Biosciences at 2.6 subject to Rule 16b-3 | 08/30/2024 |
2 | Aptose Announces Results from Special Meeting of Shareholders | 09/05/2024 |
3 | Acquisition by Ashe Carol Gail of 100000 shares of Aptose Biosciences subject to Rule 16b-3 | 09/12/2024 |
4 | Disposition of 15400 shares by Whitehead Warren of Aptose Biosciences at 3.35 subject to Rule 16b-3 | 09/23/2024 |
5 | Aptose Biosciences Inc. Short Interest Up 520.2 percent in September | 09/27/2024 |
6 | Disposition of 60000 shares by Wilson Donald R. Jr. of Aptose Biosciences at 2.62 subject to Rule 16b-3 | 10/16/2024 |
7 | Allogeneic Hematopoietic Stem Cell Transplant Market to Grow Rapidly During the Study Period DelveInsight | 10/21/2024 |
8 | Acquisition by Platzer Erich of 3333 shares of Aptose Biosciences at 2.0 subject to Rule 16b-3 | 11/01/2024 |
9 | Acquisition by Ashe Carol Gail of 3333 shares of Aptose Biosciences at 2.0 subject to Rule 16b-3 | 11/05/2024 |
10 | Aptose Biosciences GAAP EPS of -0.37 beats by 0.27 | 11/08/2024 |
11 | Aptose Biosciences Stock Price Passes Above Fifty Day Moving Average Heres Why | 11/13/2024 |
12 | Aptose Initiates TUSCANY Phase 12 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet Therapy | 11/20/2024 |
13 | Aptose Biosciences to sell 40M shares at 0.20 in public offering | 11/22/2024 |
About Aptose Biosciences Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Aptose or other stocks. Alpha measures the amount that position in Aptose Biosciences has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2023 | 2024 (projected) | Graham Number | 8.56 | 8.13 | Receivables Turnover | 0.45 | 0.4 |
Aptose Biosciences Upcoming Company Events
As portrayed in its financial statements, the presentation of Aptose Biosciences' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Aptose Biosciences' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Aptose Biosciences' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Aptose Biosciences. Please utilize our Beneish M Score to check the likelihood of Aptose Biosciences' management manipulating its earnings.
| 28th of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 28th of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Aptose Biosciences
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Aptose Biosciences Backtesting, Aptose Biosciences Valuation, Aptose Biosciences Correlation, Aptose Biosciences Hype Analysis, Aptose Biosciences Volatility, Aptose Biosciences History and analyze Aptose Biosciences Performance. To learn how to invest in Aptose Stock, please use our How to Invest in Aptose Biosciences guide.You can also try the Cryptocurrency Center module to build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency.
Aptose Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.